Kymera Therapeutics (KYMR) Operating Income (2019 - 2026)
Kymera Therapeutics (KYMR) reported Operating Income of -$84.2 million for Q1 2026, down 13.07% year-over-year from -$96.8 million in Q1 2025, and up 14.04% quarter-over-quarter from -$97.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Operating Income (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Operating Income data on file, last reported at -$84.2 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$84.2 million, down 13.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$359.1 million (down 29.08% YoY), and the FY2025 annual result was -$349.4 million, down 33.54% from the prior year.
- Operating Income improved to -$84.2 million in Q1 2026 per KYMR's latest filing, from -$97.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$19.3 million in Q4 2023 and troughed at -$97.9 million in Q4 2025.
- A 5-year average of -$60.1 million and a median of -$57.5 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income surged 50.01% in 2023, then slumped 318.16% in 2024.
- A 5-year view of Operating Income shows it stood at -$38.6 million in 2022, then surged by 50.01% to -$19.3 million in 2023, then tumbled by 318.16% to -$80.8 million in 2024, then slipped by 21.23% to -$97.9 million in 2025, then advanced by 14.04% to -$84.2 million in 2026.
- Business Quant data shows KYMR's Operating Income at -$84.2 million in Q1 2026, -$97.9 million in Q4 2025, and -$92.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -84.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.15 Mn |
| Dec 31, 2025 | -97.90 Mn |
| Sep 30, 2025 | -92.52 Mn |
| Jun 30, 2025 | -84.56 Mn |
| Mar 31, 2025 | -74.43 Mn |
| Dec 31, 2024 | -80.76 Mn |
| Sep 30, 2024 | -72.12 Mn |
| Jun 30, 2024 | -50.93 Mn |
| Mar 31, 2024 | -57.83 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -57.51 Mn |
| Jun 30, 2023 | -43.38 Mn |
| Mar 31, 2023 | -45.33 Mn |
| Dec 31, 2022 | -38.63 Mn |
| Sep 30, 2022 | -44.88 Mn |
| Jun 30, 2022 | -40.81 Mn |
| Mar 31, 2022 | -36.93 Mn |
| Dec 31, 2021 | -33.99 Mn |
| Sep 30, 2021 | -28.64 Mn |
| Jun 30, 2021 | -24.73 Mn |